Why Reaching a Physician and Resonating With One Are Not the Same Thing
Pharma marketing has made reaching physicians a science. The tooling for verified HCP audience targeting, the publisher networks, the programmatic infrastructure - all of it has been built to answer one question with increasing precision: did the right HCPs see the message? What it has not been built to answer, with anything like the same rigour, is whether the physicians being reached were actually moved by what they saw. Reach and resonance look identical in a campaign report. They produce very different outcomes in the clinic.
What Reach Measures and What It Misses
Reach, in pharma marketing terms, means an impression was delivered to a verified physician. It confirms identity - a credentialed HCP received the exposure. What it does not confirm is relevance. A cardiologist who sees a message about a therapy for a patient population they rarely treat has been reached. They have not been given anything clinically useful to them that day.
This is not a minor distinction. A physician's decision to prescribe a therapy is not triggered by exposure alone. It is triggered by exposure at a moment when the information is clinically applicable to their current practice - when they have a patient who fits the indication, when they are evaluating treatment options, when the message addresses a question they are actively asking. Without that alignment, an impression is noise.
Pharma marketing knows this intuitively. Campaign teams invest time on audience segmentation, targeting by specialty and geography, and message sequencing. Yet the metrics campaigns are ultimately evaluated against - impressions delivered, reach among target HCPs, frequency - measure exposure, not alignment. The industry has built a sophisticated system for answering who saw the message. It has not built an equally sophisticated system for answering whether the message mattered.
The Three Conditions Resonance Requires
For a pharma message to move a physician - to shift their awareness of a therapy toward clinical consideration - three conditions need to be in place simultaneously.
The first is identity match: the physician must treat patients who fit the therapy's indication. Reaching a specialist with a message about a disease outside their primary practice is low-value by definition. This is the condition pharma marketing has historically invested most in addressing, and where targeting technology has made the most progress.
The second is content relevance: the message must address something the physician is currently thinking about. Research by ZoomRx, analysing recall and effectiveness across 14,000 messages from more than 380 pharma brands, found that the message themes which resonate with HCPs vary significantly depending on where a drug is in its launch lifecycle and what clinical questions physicians are actively asking at each stage. The same message, delivered at the wrong stage, underperforms. The physician has already moved on.
The third condition is moment alignment: the message must arrive when the physician is in a clinical decision context. A physician reviewing patient charts, considering treatment options for an upcoming appointment, or engaging with clinical content is in a very different cognitive state from a physician between meetings. The same message, to the same physician, carries different weight depending on when and where it is received.
Most pharma campaigns control for the first condition. Few control for all three simultaneously.
Why the Measurement System Reinforces the Gap
The reason pharma marketing conflates reach with resonance is partly a measurement problem. Reach is countable. Impressions delivered, verified HCPs exposed, and frequency per target specialty can all be reported with precision. What cannot easily be counted is whether the physician was actively managing a patient who matched the indication at the moment of exposure.
This creates a structural incentive to optimise for what is measurable. Campaigns are built to maximise reach among verified target audiences because that is what the measurement system rewards. Whether that reach translated into clinical relevance - whether the physician connected the message to a patient they were thinking about - falls outside what standard campaign analytics can answer.
The consequence is campaigns that hit every reach metric and still fail to change prescribing behaviour. Not because the creative was weak or the targeting was wrong, but because the exposure happened outside the clinical context that would make it actionable.
The Patient at the End of the Signal Chain
This matters beyond the campaign report. A physician who is reached by a message about a therapy that would genuinely benefit one of their patients, but receives that message at a moment when it is not clinically relevant, will not act on it. The patient does not receive the therapy. The physician is not at fault. The marketing function failed to meet them where they were.
This is the version of the resonance problem the industry rarely discusses openly. It is not only a media efficiency issue. It is a gap between the information a physician needed and the moment they received it - and patients sit at the end of that chain.
What Optimising for Resonance Looks Like
The shift from reach to resonance is not a creative challenge. It is a data and infrastructure challenge. It requires knowing more about the physician than their specialty and geography - it requires understanding their clinical context: what patient population they are actively managing, what content they are engaging with, what decisions their practice is currently approaching.
Pharma marketing that accounts for these signals delivers messages at the right moment in the clinical decision cycle, not just in front of the right credentials. The physician receives information they can act on. That is what resonance looks like in practice - not a higher click-through rate, but a message that earns clinical consideration because it was relevant when it arrived.
Reach is the table stake. Resonance is the outcome that changes prescribing behaviour.
Doceree is the world's first AI-powered operating system for healthcare marketing, unifying the prescription journey from physician awareness to fill on a single platform. Learn more at doceree.ai or schedule a demo.
Frequently Asked Questions
What is the difference between HCP reach and HCP resonance in pharma marketing? Reach means an impression was delivered to a verified physician. Resonance means the message was clinically relevant at that moment. Pharma marketing measures reach and assumes it implies resonance. The two are not equivalent - optimising only for reach produces campaigns that hit audience targets without changing prescribing behaviour.
Why do pharma campaigns fail to resonate with physicians? The most common reason is a failure of clinical context, not targeting or creative. A physician may be correctly identified by specialty and geography, but if the message arrives outside a moment when it is applicable to their practice, it will not produce engagement. Resonance depends on what the physician is actively thinking about, not just who they are.
What does clinical context mean in HCP marketing? Clinical context refers to the circumstances of a physician's practice at a given moment: what patients they are managing, what treatment decisions they are approaching, what clinical content they are engaging with. Messages that account for clinical context - arriving when a physician is considering a relevant decision - are more likely to earn clinical consideration than messages that match only on specialty or geography.
How does message timing affect HCP marketing effectiveness? Significantly. ZoomRx research across 14,000 messages from 380+ pharma brands found that the themes physicians respond to change depending on the stage of a drug's launch cycle and the clinical questions they are actively asking. The same message delivered at the wrong time underperforms - not because of what it says, but because of when it arrives.